N-(3-amino-3-oxopropyl)-2-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]benzamide and its use for treating HIV infection

Patent metadata

Field	Value
Publication number	US-12551464-B2
Application number	US-202017785155-A
Country	US
Kind code	B2
Filing date	Dec 17, 2020
Priority date	Dec 17, 2019
Publication date	Feb 17, 2026
Grant date	Feb 17, 2026

Abstract

Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.

First claim

The invention claimed is:

1 . A compound of formula (I):

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3 . A method of treating or preventing a human immunodeficiency virus (HIV) infection in a mammal in need thereof comprising administering to the mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4 . The method according to claim 3 , wherein the HIV comprises a virus selected from the group consisting of HIV Clade A, HIV Clade B, HIV Clade C, HIV Clade D, HIV Clade E, HIV Clade F, HIV Clade G, and HIV Clade O.

5 . The method according to claim 3 , wherein the compound or salt is administered orally.

6 . The method according to claim 3 , further comprising administering to the mammal one, two, three, or four additional therapeutic agents.

7 . The method according to claim 6 , wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of combination drugs for HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV gene editing, and HIV vaccines, and any combination thereof.

8 . The method according to claim 7 , wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of entry inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV non-nucleotide reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and pharmacokinetic enhancers, and any combination thereof.

9 . The method according to claim 8 , wherein the additional therapeutic agents comprise a combination of antiretroviral agents selected from the group consisting of:
tenofovir, emtricitabine, and raltegravir; tenofovir, emtricitabine, and dolutegravir; abacavir, lamivudine, and dolutegravir; tenofovir, emtricitabine, and elvitegravir; and tenofovir, emtricitabine, ritonavir, and darunavir.

10 . The method according to claim 3 , which inhibits or prevents maturation of an immature human immunodeficiency virus (HIV) to a mature HIV.

11 . The method according to claim 10 , wherein the HIV comprises a virus selected from the group consisting of HIV Clade A, HIV Clade B, HIV Clade C, HIV Clade D, HIV Clade E, HIV Clade F, HIV Clade G, and HIV Clade O.

12 . The method according to claim 11 , wherein the compound or salt thereof is administered orally.

13 . The method according to claim 9 , further comprising administering to the mammal one, two, three, or four additional therapeutic agents.

14 . The method according to claim 13 , wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of combination drugs for HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV gene editing, and HIV vaccines, and any combination thereof.

15 . The method according to claim 13 , wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of entry inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV non-nucleotide reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and pharmacokinetic enhancers, and any combination thereof.

16 . The method according to claim 13 , wherein the additional therapeutic agents comprise a combination of antiretroviral agents selected from the group consisting of:
tenofovir, emtricitabine, and raltegravir; tenofovir, emtricitabine, and dolutegravir; abacavir, lamivudine, and dolutegravir; tenofovir, emtricitabine, and elvitegravir; and tenofovir, emtricitabine, ritonavir, and darunavir.

17 . The method according to claim 3 , which prevents or inhibits a human immunodeficiency virus (HIV) infection in a mammal in need thereof, wherein the mammal has at least one HIV viral particle on a surface thereof.

Assignees

• Us Health

Inventors

• Appella Daniel H
• Nikolayevskiy Herman
• Robello Marco
• Scerba Michael T

Classifications

• C07D233/92

  attached in position 4 or 5 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K39/21

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• A61K31/635

  having a heterocyclic ring, e.g. sulfadiazine · CPC title